secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001193125-26-079452
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology reports FY2025 net loss $161M; cash $903M provides runway to 1H 2029
--------------------------------------------------------------------------------

- Q4 2025 net loss $41.3M ($0.52/share) vs $31.8M ($0.46/share) in Q4 2024.
- Full-year 2025 net loss $161.0M ($2.08/share) vs $88.0M ($1.41/share) in FY2024.
- Cash, equivalents, and securities ~$903M as of Feb 26, 2026; funded into first half 2029.
- PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC expected 1H 2026.
- CORE-008 Cohort CX first combination results with gemcitabine in HR NMIBC expected 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/0001193125-26-079452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/ck0001991792-20260227.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-079452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer